Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment of patients with hepatocellular carcinoma that are candidates for locoregional therapies.

Next Previous
X
Search
Trial Profile

A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment of patients with hepatocellular carcinoma that are candidates for locoregional therapies.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms NASIR-HCC

    • Most Recent Events

    • 24 Jun 2023 Results of sub analysis (n=32) assessing health related quality of life (HRQoL) of patients with unresectablehepatocellular carcinoma (uHCC) during treatment with SIRT andthe anti-programmed cell death-1 (PD1) agent nivolumab presented at the European Association for the Study of the Liver Congress 2023
    • 03 Nov 2020 Status changed from active, no longer recruiting to completed.
    • 14 Sep 2020 Results presented in the Sirtex Medical Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top